More effective stent for high bleeding risk patients
Medtronic Bangladesh Pvt Ltd announced the clinical data from Onyx ONE Global Study. The prospective, multi-centre, randomised study assessed the clinical outcomes between two drug-eluting stents (DES) in nearly 2,000 high-bleeding risk (HBR) patients with one month of dual antiplatelet therapy (DAPT). Results were presented recently during a Late-Breaking Clinical Trial session at the 31st Transcatheter Cardiovascular Therapeutics Conference (TCT), the annual scientific symposium of the Cardiovascular Research Foundation in San Francisco.
"High Bleeding Risk patients are a complex patient population often excluded from stent and drug trials, make up nearly 40% of all percutaneous coronary intervention (PCI) patients, and a potential group that could benefit from shorter DAPT treatment," said Farrukh Alam, Country Director, Medtronic Bangladesh.
The Resolute Onyx DES encourages fast vessel healing with its proprietary BioLinx™ polymer, a bio-compatible and non-thrombogenic coating created specifically for use on DES and unique platform design featuring Continuous Sinusoid Technology (CST), which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent.
Comments